SASaidatri Arige

Saidatri Arige

*This is an algorithmically generated author record based on publicly available information.

Saidatri Arige has a total of 15 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • High Throughput Screening (HTS) and Phenotypic Screening

    by C.K. Ashok Kumar, Raveesha Peeriga, Krishnaveni Manubolu, Saidatri Arige, Vanukuri Lakshmana Vinod Kumar, Morla Devika

    Modern drug discovery heavily depends on high-throughput screening (HTS) and phenotypic screening because they provide joint methods for therapeutic candidate identification and validation. The rapid automated technology system at HTS conducts tests on numerous compounds in volumes reaching thousands to millions to detect biological target responses. The use of target-based assays within this method achieves precise and scalable results, yet fails to show the complete effects of compounds on biological structures. The screening methodology in phenotypic testing determines compound efficacy through observable changes in cell or organismal phenotypes without needing target identification. The method proves crucial for identifying drug candidates which use fresh mechanisms of action among diseases whose pathways remain difficult to understand. Through their combination, HTS enables researchers to develop potent, stable drug candidates which successfully interact with biological systems at both target and system levels. Recent innovations such as artificial intelligence and 3D cell culture systems, and organ-on-a-chip technologies have improved both efficiency and prediction capabilities of screening strategies. Researchers can quicken the creation of effective therapeutics by combining methods synergistically through their drug discovery workflow.

  • Chemical Biology Approaches in Drug Discovery

    by Raveesha Peeriga, Krishnaveni Manubolu, Shaik Sabreen, Sajja Jayanth Babu, Nagul Meeravali Shaik, Saidatri Arige

    The process of modern drug discovery heavily depends on chemical biology as a technique to connect chemical science with biological research through its provision of investigative instruments for targeting and verifying drug candidate molecules. The forms of chemical probes combined with tool compounds enable new approaches in drug research because they enable precise molecular-level studies of biological processes, thus promoting better drug development. The fundamental components of drug discovery advancement rely on both chemical probes used to specify protein modifications and experimental tool compounds that help understand biological systems. Extensive disease mechanisms such as those in oncology, neurodegenerative diseases, and infectious diseases become transparent through these investigation methods, which traditional approaches fail to reveal. Extensive expansion of chemical probe libraries targeting multiple disease types will enable better comprehension of complex biological structures. The advances demonstrate significant potential for precision medicine by delivering better and segmental therapeutic approaches to treat complex diseases. The field of drug discovery experiences transformative improvements through chemical biology methods that introduce novel strategies for medical management difficulties.

  • Target Identification and Validation

    by Raveesha Peeriga, Krishnaveni Manubolu, Aminabee Shaik, Saidatri Arige, Jahasultana Mohammed, Vanukuri Lakshmana Vinod Kumar

    This chapter covers target identification and validation processes in drug discovery together with their historical methods and contemporary approaches supported by new technology. The examination discusses traditional methods based on phenotypic screening together with serendipitous discoveries versus contemporary approaches utilizing high-throughput technologies along with computational models. This section of the chapter emphasizes the revolutionary contribution of genomics along with proteomics to new drug target discovery. Genomic technologies include next-generation sequencing (NGS) and genome-wide association studies (GWAS) to reveal both genetic variations and disease-related connections between them. Through proteomics, scientists can extend genomics knowledge because the technology shows proteins in detail alongside their connection patterns and functional behavior, contributing to full cellular system insights. These technologies help scientists detect new targets while validating the therapeutic value of these targets for cancer and neurodegenerative disorders, as well as cardiovascular diseases and metabolic disorders and infectious diseases and autoimmune conditions. The chapter stresses that valid drug targets need comprehensive preclinical along with clinical testing to show their practical value for creating new drugs, which leads to individualized medical therapies.

  • Open Access

    Digital Dermoscopy: Advancements in Skin Cancer Diagnosis and Monitoring

    by Saidatri Arige, Lakshmana Rao Atmakuri, Rasheed Shaik, Manasa Gude, Vijaya Kumar Ghanta, Ramesh Alluri

    Digital dermoscopy is an advanced, non-invasive imaging technique that enhances conventional dermoscopy by utilizing computerized imaging technology to assess skin lesions, aiding in the early-stage diagnosis of skin cancers, including melanoma, basal cell carcinoma (BCC) and squamous cell carcinoma (SCC). This technique provides high-resolution images, enabling detailed examination and magnification of lesions, which helps clinicians identify subtle changes in lesion morphology over time. Additionally, it allows for long-term monitoring through serial imaging, facilitating more accurate follow-up assessments. Integrating Artificial Intelligence (AI) and machine learning algorithms has significantly improved diagnostic accuracy by enhancing the detection of malignancies, allowing for faster and more reliable analysis of dermoscopic images. Despite its advantages, digital dermoscopy faces several challenges that limit its widespread use. Image quality can be compromised by device limitations, lighting conditions, and operator proficiency, which can affect the accuracy of diagnoses. Furthermore, the technique remains heavily dependent on clinician expertise, as the interpretation of dermoscopic images is complex and requires specialized training. Moreover, the integration of digital dermoscopy into electronic health records (EHR) and telemedicine systems presents logistical and financial challenges, including issues related to data storage, accessibility, and reimbursement. This review provides an in-depth examination of the principles, advantages, limitations and prospects of digital dermoscopy, focusing on its potential to advance dermatological practice through improved diagnostic capabilities, more efficient patient management, and enhanced early detection of skin cancers.